PeptiGrowth was established in April 2020 as a joint venture between Mitsubishi Corporation and PeptiDream Inc. Its mission is to contribute to the growth of the regenerative medicine and cell therapy industry through innovative solutions. Since its foundation, PeptiGrowth has been working on the development of a series of synthetic peptides that have the same functions as the conventional growth factors and cytokines by joint development with PeptiDream.

Following HGF-Alternative Peptide and TGFβ1 inhibitor, PeptiGrowth is planning to launch the next series of growth-factor alternatives in 2022 to serve humanity.